Subtype
Diffuse Glioma
CI-CAN-00002519Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002519Explore in graph →
Clinical trials
2,804 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03206021 | COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors(COZMOS) | completed | Phase 1 | 31 | The Hospital for Sick ChildrenOTHER | 3 | Apr 5, 2024 | clinicaltrials |
| NCT03326388 | Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours(INSPECT) | completed | Phase 1 / Phase 2 | 14 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03466450 | Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma(GEINOGLAS) | completed | Phase 1 / Phase 2 | 75 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02052648 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | completed | Phase 1 / Phase 2 | 160 | NewLink Genetics CorporationINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT02869243 | A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients | completed | Phase 1 | 15 | StemgenINDUSTRY | 3 | Feb 16, 2024 | clinicaltrials |
| NCT01661400 | Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors(ASCR) | completed | Phase 1 | 14 | Washington University School of MedicineOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01922076 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 31, 2024 | clinicaltrials |
| NCT01811498 | Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM | completed | Phase 1 / Phase 2 | 31 | Northwell HealthOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02457845 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | completed | Phase 1 | 13 | Gregory K. Friedman, MDOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT04552886 | Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma | completed | Phase 1 | 17 | The Cooper Health SystemOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT01502917 | Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy | completed | Phase 1 | 50 | Y-mAbs TherapeuticsINDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04264143 | CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas | completed | Phase 1 | 9 | Luca SzalontayOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT01421524 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | completed | Phase 1 | 271 | CelgeneINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT02315534 | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | completed | Phase 1 / Phase 2 | 34 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Nov 15, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03425292 | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | completed | Phase 1 | 49 | Saint John's Cancer InstituteOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02644460 | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors(AflacST1501) | completed | Phase 1 | 53 | Emory UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02313272 | Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02780804 | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02575794 | Terameprocol in Treating Patients With Recurrent High Grade Glioma | completed | Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02658981 | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | completed | Phase 1 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01491893 | PVSRIPO for Recurrent Glioblastoma (GBM)(PVSRIPO) | completed | Phase 1 | 61 | Istari Oncology, Inc.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03158389 | NCT Neuro Master Match - N²M² (NOA-20)(N²M²) | completed | Phase 1 / Phase 2 | 228 | University Hospital HeidelbergOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04119674 | Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Zhejiang Cancer HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02386826 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 1 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00634231 | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | completed | Phase 1 | 8 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas(BrTK01) | completed | Phase 1 | 15 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT02619864 | mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme | completed | Phase 1 | 15 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02022644 | Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma | completed | Phase 1 | 18 | University of California, San FranciscoOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03726515 | CART-EGFRvIII + Pembrolizumab in GBM | completed | Phase 1 | 7 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02661282 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | completed | Phase 1 / Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04757662 | Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT01081223 | Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma | completed | Phase 1 / Phase 2 | 12 | TVAX BiomedicalINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT02238496 | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | completed | Phase 1 | 10 | Andrew B Lassman, MDOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT04091503 | Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | completed | Phase 1 | 30 | Center Trials & Treatment EuropeNETWORK | 3 | Apr 25, 2023 | clinicaltrials |
| NCT02444546 | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | completed | Phase 1 | 6 | Mayo ClinicOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT03849105 | 131I-IPA and Concurrent XRT in Recurrent GBM(IPAX-1) | completed | Phase 1 / Phase 2 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
| NCT03086616 | CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009) | completed | Phase 1 | 6 | Sabine Mueller, MD, PhDOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT03178032 | Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 12 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04089449 | A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas | completed | Phase 1 | 86 | Prelude TherapeuticsINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04205357 | Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma(SAS-GKRS) | completed | Phase 1 | 24 | Haukeland University HospitalOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT01269424 | BG & TMZ Therapy of Glioblastoma Multiforme | completed | Phase 1 | 10 | Stanton Gerson MDOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT01792310 | A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 54 | Laminar PharmaceuticalsINDUSTRY | 2 | Feb 21, 2023 | clinicaltrials |
| NCT03867123 | A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients | completed | Phase 1 | 18 | Laminar PharmaceuticalsINDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03072134 | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT02829931 | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Apr 8, 2024source: clinicaltrials